Thesis: Why the FDA Is Now the More Likely First Approver of Blarcamesine — and Why EMA Will Follow
(A reasoned hypothesis — not a guarantee. Tone: measured, rational, Vegas-style odds handicapping.)
Executive Summary
Blarcamesine’s European review did not culminate in approval this November, but the decision to continue the process rather than terminate it is key. EMA did not issue a marketing denial and Anavex did not withdraw - an outcome that only makes strategic sense if the sponsor believes a viable path forward exists.
The most defensible interpretation of the current posture is that the regulatory baton is shifting from EMA to FDA, not because the drug failed scientifically, but because macroeconomic and political incentives in the U.S. are now aligned for a first-in-class Alzheimer’s approval, while Europe has chosen caution to avoid being first.
In short:
The science appears strong enough to approve somewhere. The question is: who wants to be first?
The evidence suggests the United States does — and before the 2026 midterm election cycle hits full gear.
Why the FDA Has the Incentive to Go First
2026 is a political mid-term election cycle year in the US. Importantly, all 435 seats in Congress are up for election and 1/3 of the Senate. This is a crucial election cycle to the current administration. They have the ability to use the agencies they now control to sway voters. It’s not an obligation but it is dependable that they deliver substantial motivation to key voting blocs and demographics prior to major elections in order to retain control, and widen their lead, to the extent possible. This happens with both parties - not a single party trait.
The United States has a pattern - and a political incentive - to be the global pioneer on major medical breakthroughs.
Alzheimer’s, in particular, represents:
The introduction of this voucher by the FDA, put in place by the current Administratiom, in the middle of the EMA review window was not random. It is a structural signal that:
A mechanism now exists for the U.S. to fast-track the next Alzheimer’s drug with a reasonable efficacy and safety profile.*
If Blarcamesine succeeds, the public credit is personal, not institutional:
Senators,
FDA leadership,
Presidential hopefuls
can stand in front of cameras and say:
“We delivered the first effective oral Alzheimer’s treatment to American families.”
That headline is worth votes - a reality no political strategist denies.
Why EMA Stopped Short of Approval - Without Walking Away
If EMA had lost faith, three things would have happened:
Outcome if EMA doubted viability:
Withdrawn by sponsor - as early as the first clock stop, likely
Negative opinion issued
Conditional approval denied and case closed
What actually happened:
No withdrawal
No rejection
Oral Explanation
What the EMA actually did was tell Anavex:
“We are willing to continue evaluating. But Europe does not want to jump first.”
EMA had everything needed to grant conditional approval. Instead, it blinked.
Regulatory bodies rarely phrase this explicitly, but the message is clear:
This is consistent with the Kisunla and Lecanemab precedents - both approved in the U.S. first, and adopted in Europe shortly afterward.
In Alzheimer’s:
FDA tends to validate first. EMA tends to solidify second.
Why the OLE Data Changes the Game (Even If EMA Didn’t Pull the Trigger)
For 48 weeks, Blarcamesine showed:
statistically significant cognitive benefit
but non-significant ADL benefit
This initially held the drug back.
But the 144-week OLE showed:
both cognition and ADL preserved - with magnitude greatest when the disease usually accelerates
This aligns perfectly with the sigmoidal Alzheimer’s trajectory:
In mild disease: cognition changes, ADL doesn’t
Later: ADL divergence becomes the truest clinical signal
FDA and EMA have already acknowledged that ADL is not meaningful for mild AD. Guidance simply hasn’t caught up to consensus yet.
Thus, the OLE data is exactly what a disease-modifying therapy should look like.
The science is not the problem.
Based on the OLE results:
during the downward slope of the “S” (sigmoidal trajectory, not linear, disease rate accelerates after first 3 years, acknowledged by current science - non- homogeneous population with sigmoidal “S” shaped overall trajectory), the accelerated rate of decline has been flattened in the strongest performing cohort (emphasis). That’s the kind of breakthrough which requires an authorization from the highest power base (in this case US FDA). It also commands the highest political capital (which EMA doesn’t need because they aren’t elected heads of state and 27 countries share in it). Additionally, it carries the largest accountability - US can take the hit if this fails (polarizing figures and been through worse…Aduhelm, etc); Europe cannot withstand loss of confidence in their regulatory decisions.
The pressure of being first is the problem.
Why Anavex’s Public Response Matters
The company’s post-decision language thanked EMA “for the work and learning accomplished together through this process” (paraphrase) - polite, diplomatic, and very characteristic of how companies speak when:
the first teacher has taken them as far as possible, and
the next advancement will occur somewhere else
Missling said, “We look forward to continued interactions with global regulatory bodies” (paraphrase).
The wording carried no defensiveness, no blaming, no retreat.
A company facing a dead end withdraws.
A company facing a new front appeals and continues.
And they appealed immediately - not after regrouping. During Market hours on a bloodbath day.
That is not a wounded stance. That is a mobilizing stance.
Missling is the largest individual shareholder. Why would he bluff if the biggest losers would be shareholders? - himself included and leading the pack?
Vegas-Style Odds Handicapping (Not Guarantees — Just Logic)
Based on incentives, precedents, and timeline alignment, a reasonable speculative model might look like this:
Scenario
Odds
(conceptual not financial advice)
FDA first approval (full or conditional)
>50%
FDA delays but eventually approves
~ 30%
EMA reverses before FDA and approves first
~ 15%
Neither regulator approves (final failure)
< 5 - 10% based on safety + OLE data strength
These are not certainties, simply a rational bookmaker’s distribution based on:
scientific data
precedent patterns
regulatory incentives
political timing
refusal of sponsor to withdraw
refusal of EMA to terminate
A drug that is failing does not make it this far.
A drug that is failing does not trigger an immediate FDA strategic meeting request.
A drug that is failing does not get appealed - because appeals are expensive, public, and risky.
The Path Forward
If this thesis is correct, the sequence looks like:
Not because FDA dictates EMA -
but because once the U.S. steps first, the risk of being wrong disappears for Europe.
And that is the core insight:
EMA hesitated not because the drug is weak - but because being first carries political and financial risk.
If a drug can’t swim, it sinks. They could not sink it after 210 days.
FDA, on the other hand, is positioned to benefit from being first.
Closing Thoughts
This thesis does not claim inevitability.
- The strategy is sound for any AD potential drug which improves current outcomes, lowers costs, lessens side effects and shows up on time. That may or may not be Blarcamesine. Wait to see.
It claims alignment:
scientific,
regulatory,
economic,
political.
And when all four align, the odds change.
If Blarcamesine succeeds, it will be because:
the signal was real,
the safety was clean,
the unmet need was enormous,
and the right regulator wanted to make history.
If it fails, it will be because the signal was not strong enough - not because the logic here was flawed.
Either way, it is no longer EMA-first science.
It is now FDA-first chess.
It was the FDA saying:
We are allowed to accelerate reviews when there is public health urgency, so we’re creating a pilot voucher system we control ourselves.
No vote required. No multi-year implementation.
Why there were suddenly so many (9 + 6)
The FDA telegraphed - quietly - that the first wave of vouchers would be ushered in to normalize the process.
In other words, the first 15 weren’t “everyone who deserved one”.
It now becomes the single most powerful market incentive in biotech since Breakthrough Therapy Designation.
Why this matters for Alzheimer’s drugs in particular
Of the 15 recipients:
7 are oncology
3 are addiction / mental health
2 are rare disease
1 is obesity
0 are Alzheimer’s… yet
And Alzheimer’s is broadly regarded (by NIH/CDER leadership) as:
the #1 U.S. public health cost emergency
Going forward, Alzheimer’s is not going to be excluded.
The FDA is now positioned to:
take a political & scientific victory lap for a first-in-class Alzheimer’s drug
without waiting for other regulators to lead
and without having to change statutory law first
This is exactly the kind of drug the CNPV was designed to grease the path for — high unmet need + safe + scalable + innovative mechanism.
So why didn’t they hand out a voucher to an Alzheimer’s drug yet?
Too soon. Timing needs to align with the election cycle currency of the senior and caregiver votes.
AI
Market Data 
Markets 
